| 今开：20.65 | 昨收：20.74 |
| 最高：20.8199 | 最低：20.38 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.741233766E9 |
Syndax(SNDX)04-03 04:35
$Syndax(SNDX)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-040230 Act: 34 Size: 2 MB 网页链接查看全文
Syndax(SNDX)03-18 19:15
$Syndax制药(SNDX)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0000950170-24-032514 Act: 34 Size: 469 KB 网页链接查看全文
Syndax(SNDX)02-28 06:25
$Syndax制药(SNDX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-048118 Act: 33 Size: 86 KB 网页链接查看全文
Syndax(SNDX)02-28 05:05
$Syndax制药(SNDX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-021086 Act: 34 Size: 359 KB 网页链接查看全文
Syndax(SNDX)02-28 06:35
$Syndax制药(SNDX)$ S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers Accession Number: 0001193125-24-048135 Act: 33 Size: 2 MB 网页链接查看全文
Syndax(SNDX)02-28 05:45
$Syndax制药(SNDX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-021253 Act: 34 Size: 12 MB 网页链接查看全文
Syndax(SNDX)02-10 05:05
$Syndax制药(SNDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001218 Size: 7 KB 网页链接查看全文
Syndax(SNDX)02-10 05:05
$Syndax制药(SNDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001217 Size: 7 KB 网页链接查看全文
Syndax(SNDX)02-08 23:25
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902219-24-000134 Act: 34 Size: 37 KB 网页链接查看全文
Syndax(SNDX)02-14 10:45
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001234 Act: 34 Size: 167 KB 网页链接查看全文
确定性required03-25 20:06
$Syndax制药(SNDX)$ 在2024年预计将取得以下主要成果：
Axatilimab的生物制品许可申请（BLA）获得FDA的优先审查：Axatilimab是一种针对慢性移植物抗宿主病（GVHD）的治疗药物，FDA已接受其BLA并授予优先审查地位，审批决定预计将在2024年8月28日前做出。
Revumenib的新药申请（NDA）提交给...查看全文
chuminhua2023-10-03 12:05
10/2，Syndax Pharmaceuticals $Syndax制药(SNDX)$ 周一报告称，revumenib 的 I/II 期研究在某些急性白血病患者中实现了其主要目标，尽管结果低于投资者的预期，并且出现了安全信号。 一个独立的数据监测委员会建议提前停止 AUGMENT-101 试验，该公司表示计划在年底前向 FDA 申请这个口服 menin 抑...查看全文
产业链观察2023-10-02 17:31
#药闻简讯# $Syndax制药(SNDX)$ A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) $Kura Oncology(KURA)$查看全文
陈岭谈药2023-07-30 08:57
继续为您梳理过去一周国内国际Top药闻：
一.国内药闻：
1.正大天晴曲妥珠单抗获批上市: 正大天晴宣布其研发的曲妥珠单抗生物类似药（TQ-B211，商品名：赛妥）获批上市，批准用于HER2阳性早期乳腺癌、转移性乳腺癌及转移性胃癌的治疗。该产品为继汉曲优（复宏汉霖）、安瑞泽（博锐生物）之...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日，$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布，抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病（GVHD）成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验，共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
不入流资讯2023-07-24 19:29
$Syndax制药(SNDX)$ Contango ORE tumbles 25% premarket on underwritten public offering
Contango ORE因承销的公开发行在盘前股价下跌25%。这是ChatGPT翻译的信息。查看全文
不入流资讯2023-07-24 19:28
$Syndax制药(SNDX)$ Syndax soars 30% premarket after trial primary endpoint Syndax在临床试验中主要终点达成后，盘前股价飙升30%。来自ChatGPT翻译查看全文
牛唐2023-06-14 15:55
医药板块速评（2022.06.12）
1、RNAi疗法赛道涨幅较少，哪些公司值得关注？
2、$Syndax制药(SNDX)催化剂在即，是否有配置机会？
3、$小鹏汽车(XPEV)$ 、$苹果(AAPL)$ 、$中概互联网指数ETF-KraneShares(KWEB)$ 等期权异动，后续走势如何看？查看全文
产业链观察2022-12-05 20:42
#药闻简讯# $Syndax制药(SNDX)$ 宣布Revumenib治疗复发性或难治性KMT2A重排（MLLr）急性白血病的成人和儿童患者获得美国FDA的突破性疗法认证查看全文
智通财经APP预告，2021年5月12日，港美股上市公司活动及香港重要财经会议信息情况如下： 00:00 AECOM(ACM.US) AECOM(ACM.US)2021年第一季度业绩电话会 网络转播 04:30 Syndax Pharmaceuticals Inc(SNDX.US) Syndax Pharmaceuticals Inc(... 网页链接
$Syndax(SNDX)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-040230 Act: 34 Size: 2 MB 网页链接
$Syndax(SNDX)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-040099 Act: 34 Size: 6 MB 网页链接
$Syndax(SNDX)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-040128 Act: 34 Size: 2 MB 网页链接
$Syndax制药(SNDX)$ 8-K Current report, items 5.02, 7.01, and 9.01 Accession Number: 0000950170-24-032514 Act: 34 Size: 469 KB 网页链接
$Syndax制药(SNDX)$ S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers Accession Number: 0001193125-24-048135 Act: 33 Size: 2 MB 网页链接
$Syndax制药(SNDX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-048118 Act: 33 Size: 86 KB 网页链接
$Syndax制药(SNDX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-021253 Act: 34 Size: 12 MB 网页链接
$Syndax制药(SNDX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-021086 Act: 34 Size: 359 KB 网页链接
$Syndax制药(SNDX)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001085146-24-001353 Act: 34 Size: 44 KB 网页链接
$Syndax制药(SNDX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-24-001533 Act: 34 Size: 102 KB 网页链接